Company / FCF Margin
Perspective Therapeutics, Inc. FCF Margin History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-274.1%
FY2022
5-year range
-400.8% / -91.5%
FY2018-FY2022
Trend
-19.0%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -261.3% to -274.1% over the past 2 years.
Based on SEC 10-K filings.
-274.1% in FY2022 with a 5-year CAGR of -194.7%.
Declined from -261.3% to -274.1% over the past 2 years.
FCF Margin over time
Growth rates
- 3-Year Change
- +126.7pp
- 5-Year Change
- -194.7pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2022, fcf margin decreased 19.0% year-over-year.
- Peak fcf margin was recorded in FY2013.
- Lowest fcf margin in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.43 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | -274.1% | -19.0% |
| FY2021 | -230.4% | +11.8% |
| FY2020 | -261.3% | +34.8% |
| FY2019 | -400.8% | -338.1% |
| FY2018 | -91.5% | -15.3% |
| FY2017 | -79.3% | -3.1% |
| FY2016 | -77.0% | -13.7% |
| FY2015 | -67.7% | +0.0% |
| FY2014 | -67.7% | -37.1% |
| FY2013 | -49.4% | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026